Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Institut Català d'Ornitologia · Institut Català d'Oncologia · +47 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
5,518
total citations
- FWCI
- 369.55
- Percentile
- 100%
- References
- 23
Citations per year
Authors
57- RRRafael RosellCorresponding
Institut Català d'Ornitologia, Institut Català d'Oncologia, USP Institut Universitari Dexeus
- ECEnric Carcereny
Institut Català d'Ornitologia, Institut Català d'Oncologia
- RGRadj Gervais
Centre François Baclesse
- AVA. Vergnenègre
Hôpital Dupuytren
- BMBartomeu Massutí
Hospital General Universitario de Alicante Doctor Balmis
Topics & keywords
Topics
Keywords
- Erlotinib
- Medicine
- Docetaxel
- Internal medicine
- Oncology
- Carboplatin
- Gemcitabine
- Lung cancer
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.